SynBio Pharma — Completed patient enrollment in the Phase IV clinical trial of brincidofovir (BCV) for progressive multifocal leukoencephalopathy (PML).

On the 9th, Symbio Pharmaceuticals <4582> announced that it has entered into a clinical Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH), and has completed enrollment of the first patient (First Patient In) in its ongoing clinical trial of intravenous brincidofovir (IV BCV) for progressive multifocal leukoencephalopathy (PML). The trial is being conducted at the NIH Clinical Center in Bethesda, Maryland.

Fisco JapanJun 9 20:53 ET

Shin Bio Pharmaceutical---Establishment of a stable supply system for ultra-high sensitivity (pico-level) immunochromatography.

Shin BioPharma <4582> announced on the 18th that it has entered into basic agreements with Nippon Steel Chemical & Material for the supply of nanocomposite particles, which form the foundation of its ultra-sensitive immunochromatography system under development, and with Nippon Gene for the manufacturing of ultra-sensitive test kits. Moving forward, Shin BioPharma will collaborate with both companies to commercialize a testing system capable of detecting trace amounts of target antigens. The establishment of these supply agreements with both companies marks an important step in this process.

Fisco JapanMay 18 20:30 ET

Change in shareholding report for Shin Bio Pharma (22.44% → 28.30%) by Evo Fund, etc.

Submitter: Evo Fund Submission Date and Time: May 13, 2026, 11:33 Submitted Document: Amendment Report (Cover Page = Amendment Report No. 23) Report Obligation Trigger Date: May 1, 2026 Reason for Amendment Report Submission: The holding percentage of stock certificates increased by more than 1%. Issuer: <4582> Shinbio Pharmaceutical Co., Ltd. Summary Table: Holding Percentage: 28.30%

Jiji PressMay 12 22:36 ET

Symbio Pharmaceuticals --- Joint research contract for PTLD extended by three years.

Shin BioPharma <4582> announced on the 12th that it has extended its Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), under the National Institutes of Health (NIH), for an additional three years to target post-transplant lymphoproliferative disorder (PTLD). The contract period has been extended until April 2029, and efforts will continue to advance the development of a treatment using Brincidofovir (BCV) for EB virus-related diseases. The company entered into the CRADA with NIH/NIAID in April 2023.

Fisco JapanMay 12 21:42 ET

Change in shareholding report for Shin Bio Pharma (22.90% → 22.44%) by Evo Fund, etc.

Submitter: Evo Fund Submission Date and Time: May 8, 2026, 14:17 Submitted Document: Amendment Report (Cover Page = Amendment Report No. 22) Trigger Date for Reporting Obligation: April 27, 2026 Reason for Amendment Report Submission: Change in the breakdown of held securities Issuer: <4582> Shinbio Pharmaceutical Co., Ltd. [Summary Table] Ownership Percentage: 22.44% Previous Percentage:

Jiji PressMay 8 01:20 ET

Synbio Pharmaceuticals---In Q1, the company steadily advanced its efforts toward the development of BCV and the commercialization of IVD.

Shin Bio Pharmaceutical (<4582>) announced its consolidated financial results for the first quarter of the fiscal year ending December 2026 (January-March 2026) on the 7th. Revenue decreased by 11.6% year-over-year to 233 million yen, operating loss amounted to 2.341 billion yen (compared to a loss of 1.169 billion yen in the same period last year), ordinary loss reached 2.390 billion yen (versus a loss of 1.288 billion yen last year), and the net quarterly loss attributable to parent company shareholders was 2.401 billion yen (compared to a loss of 1.321 billion yen last year). The group aims to achieve a specific ratio between domestic and overseas sales revenue by 2030.

Fisco JapanMay 7 22:06 ET